Evercore ISI on Travere Therapeutics (TVTX): 'We think the stock remains undervalued'
Tweet Send to a Friend
Evercore ISI analyst Liisa Bayko reiterated an Outperform rating and $11.00 price target on Travere Therapeutics (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
